BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
BIOMARIN PHARMACEUTICAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$54.67−0.01 (-0.02%)
Close on Oct 19, 2026
- Market cap
- $10.63B
- P/E (TTM)
- 143.9
- Dividend yield
- –
Biomarin Pharmaceutical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Market Cap | $10.58B | $197.05M |
| Enterprise Value | $13.89B | $106.56M |
| PE Ratio | 143.87 | 20.52 |
| PS Ratio | 3.11 | 3.93 |
| PB Ratio | 1.67 | 2.14 |
| P/TBV Ratio | 13.45 | 2.46 |
| P/FCF Ratio | 14.34 | 18.25 |
| P/OCF Ratio | 12.35 | 13.78 |
Enterprise value
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| EV / Sales | 4.08 | 2.69 |
| EV / EBITDA | 45.97 | 14.86 |
| EV / EBIT | 93.09 | 19.00 |
| EV / FCF | 18.82 | 21.02 |
Income (trailing twelve months)
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Revenue | $3.41B | $57.94M |
| Gross Profit | $2.59B | $90.47M |
| Operating Income | $149.26M | -$21.44M |
| Pretax Income | $149.11M | -$14.45M |
| Net Income | $72.97M | -$22.46M |
| EBITDA | $302.23M | -$16.91M |
| EPS (Diluted) | $0.38 | -$0.83 |
Margins
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Gross Margin | 76.1% | 52.3% |
| Operating Margin | 4.38% | -44.5% |
| Pretax Margin | 4.38% | -13.0% |
| Profit Margin | 2.14% | -39.2% |
| EBITDA Margin | 8.87% | -31.3% |
| FCF Margin | 21.7% | -8.85% |
Returns
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Return on Equity (ROE) | 1.18% | -53.1% |
| Return on Assets (ROA) | 0.76% | -41.0% |
| Return on Invested Capital (ROIC) | 1.05% | -32.0% |
| Return on Capital Employed (ROCE) | 1.48% | -37.8% |
Growth
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 11.2% | 6.01% |
| Net Income Growth (YoY) | -88.9% | -37.7% |
| EPS Growth (YoY) | -88.7% | -29.2% |
| FCF Growth (YoY) | 6.23% | 2.34% |
| Revenue Growth (3Y CAGR) | 15.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 11.6% | 6.42% |
| EPS Growth (3Y CAGR) | 33.9% | -0.17% |
| EPS Growth (5Y CAGR) | -16.7% | 3.77% |
Balance sheet
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $874.01M | $62.42M |
| Total Debt | $4.19B | $120.13M |
| Net Cash (Debt) | -$3.31B | $15.68M |
| Net Cash Per Share | -$17.11 | $0.65 |
| Equity (Book Value) | $6.32B | $48.79M |
| Book Value Per Share | $32.66 | $1.36 |
| Tangible Book Value | $786.58M | $23.06M |
| Working Capital | $2.31B | $75.77M |
Financial position
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Current Ratio | 2.39 | 3.30 |
| Quick Ratio | 1.16 | 2.39 |
| Debt / Equity | 0.66 | 0.51 |
| Debt / EBITDA | 13.85 | 3.35 |
| Debt / FCF | 5.67 | 5.05 |
| Net Debt / EBITDA | 10.96 | 2.22 |
| Interest Coverage | 1.97 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Operating Cash Flow | $857.09M | -$12.35M |
| Capital Expenditures | -$118.91M | -$1.06M |
| Free Cash Flow | $738.18M | -$20.28M |
| FCF Per Share | $3.81 | -$0.41 |
Efficiency
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Asset Turnover | 0.36 | 0.38 |
| Inventory Turnover | 0.52 | 2.67 |
| Revenue Per Employee | $1.06M | $398.96K |
| Profits Per Employee | $22.66K | -$732.08K |
| Employee Count | 3,221 | 73 |
Dividends and yields
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Earnings Yield | 0.69% | -21.2% |
| FCF Yield | 6.98% | -7.64% |
Shares
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Shares Outstanding | 193,574,000 | 59,128,900 |
| Shares Change (YoY) | -0.56% | 11.1% |
| Shares Change (QoQ) | 0.14% | 0.54% |
| Float | 192,555,000 | 48,744,500 |
| Shares Held by Insiders | 0.53% | 11.8% |
| Shares Held by Institutions | 101.1% | 59.4% |
Taxes
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Income Tax | $76.14M | $91.50K |
| Effective Tax Rate | 51.1% | 20.6% |
Scores
| Measure | Biomarin Pharmaceutical | Industry median |
|---|---|---|
| Graham Number | $16.71 | $17.36 |
| Graham Upside | -69.4% | -45.5% |
| Altman Z-Score | 1.78 | 0.10 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.82 | -2.62 |
Calculated by StockData from Biomarin Pharmaceutical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.